For individuals with type 2 diabetes, continuous glucose monitoring (CGM) devices may one day become the standard of care, according to Abbott Laboratories Inc.
ADA 2020: Abbott Expects CGM To Reduce Insulin Needed For Type 2 Diabetes
Research presented at this year’s virtual American Diabetes Association meeting demonstrated the benefits of continuous glucose monitoring for those with type 2 diabetes not taking insulin. Mahmood Kazemi, divisional VP for global medical and scientific affairs at Abbott’s diabetes care tells Medtech Insight how he sees CGM technology transforming the future of diabetes management.
